.png){kind=icon}
.png){kind=icon}
Return
Ginsenoside F1 as a novel hepatic β3-adrenergic receptor agonist for microbiota-independent cholesterol clearance
.png){kind=icon}
PRE
AI
W
X
J
Y
X
P
J
J
Y
Y
Y
DOI：10.1016/j.phymed.2026.158475.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Hypercholesterolemia remains a major modifiable risk factor for cardiovascular diseases, calling for innovative strategies to enhance cholesterol clearance beyond conventional approaches. Ginsenoside F1 (GF1), a highly bioavailable ginseng metabolite, shows various pharmacological activities, but its cholesterol-lowering potential remains unclear.
Keywords:
β3-AR agonism
Ginsenoside F1
Hypercholesterolaemia
Cholesterol catabolism
Cholesterol efflux
ABX
,
antibiotics
BAs
,
bile acids
Cho-hepatocytes
,
hypercholesterolemic hepatocyte model
EE
,
energy expenditure
ER
,
endoplasmic reticulum
FC
,
free cholesterol
GF1
,
ginsenoside F1
HCD
,
high-cholesterol diet
HPLC
,
high-performance liquid chromatography
LDL-C
,
low-density lipoprotein cholesterol
ND
,
normal diet
RER
,
respiratory exchange ratio
SCP2, sterol carrier protein 2
TC
,
total cholesterol
TG
,
triglyceride
VCO₂
,
carbon dioxide production
VO₂
,
oxygen consumption
β3-AR
,
β3-adrenergic receptor
Journal
IF:
8.3
Papers:
9.0K
Citations:
3.1W
Organization
No organization information available
Cited Papers